Press Release

Aptorum Group Launches Infectious Disease Liquid Biopsy Subsidiary, Announces Exclusive In-license from Singapore-based Accelerate Technologies to Co-Develop Molecular Based Rapid Pathogen Diagnostics to Track Pathogenic Genome
Sep 29, 2020 18:35 JST

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ) ("Aptorum Group" or "Aptorum"), a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases, announced its launch of Aptorum Innovations
More info..

Aptorum Group to Hold Investor Webinar and Present at The Wall Street Investor Forum on September 10
Sep 08, 2020 15:52 JST

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a biopharmaceutical company focused on novel therapeutics including the development of next-generation approach therapeutics targeting antimicrobial resistance, today announced President and Executive Director
More info..

Aptorum Group Joins the BEAM Alliance To Combat Antimicrobial Resistance
Sep 08, 2020 15:46 JST

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group"), a biopharmaceutical company focused on novel therapeutics including the development of next-generation therapeutics targeting antimicrobial resistance, today announced it joined the Biotech companies in Europe combating Antimicrobial Resistance Alliance based in Europe (the "BEAM Alliance") as full member.
More info..

Aptorum Group Announces Further Positive Data on ALS-4 against MRSA Wound Infection and MRSA Bacteraemia against Linezolid and Vancomycin Respectively in In Vivo Models
Sep 01, 2020 16:41 JST

Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) ("Aptorum Group"), a biopharmaceutical company focused on novel therapeutics including the development of next-generation approach therapeutics targeting antimicrobial resistance
More info..

Aptorum Group Announces Further Positive Data on SACT-1 Against Neuroblastoma and Other Potential Tumor Types Sep 01, 2020 16:32 JST Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of novel therapeutics including orphan diseases and oncology indications More info..

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2020
Sep 01, 2020 16:20 JST

Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) ("Aptorum Group"or the "Company"), a biopharmaceutical company focuses on the development of novel therapeutics to address global unmet medical needs, today provided a business update and announced financial results for the six months ended June 30, 2020.
More info..

Aptorum Group Becomes the First Nasdaq Listed Biopharmaceutical Company Admitted to Trading on Euronext Paris Stock Exchange Under the Ticker Symbol APM
Jul 27, 2020 15:18 JST

Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group"), a biopharmaceutical company focusing on the development of novel therapeutics to address global unmet medical needs
More info..

Aptorum Group Collaborates with Covar Pharmaceuticals to Investigate 3 Repurposed Drug Candidates (SACT-COV19) for Coronavirus Disease 2019 (COVID-19) under Existing Smart-ACT Platform and Acticule Infectious Disease Platform
Mar 30, 2020 22:09 JST

Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of novel therapeutics for unmet needs including but not limited to infectious, orphan and metabolic disease areas
More info..

Aptorum Group Limited Corporate Update and To Hold Q1 2020 Investor Update Call To Discuss Recent Development and Pipeline Progress
Mar 30, 2020 21:44 JST

Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today provides an update on the Company's operations in light of the recent declaration of the coronavirus outbreak as a pandemic declared by the World Health Organisation on March 11, 2020.
More info..

Aptorum Group Commences Commercialization of Dioscorea Opposita Bioactive Nutraceutical Tablets and Signed Sales Distribution Agreement in Hong Kong
Feb 24, 2020 20:13 JST

Aptorum Group Limited ("Aptorum Group"), a pharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces the commercialization of its dietary supplement for women undergoing menopause and experiencing related symptoms.
More info..

Aptorum Group Announces Further Positive Data for its ALS-4 Small Molecule Anti-virulence (Non-bactericidal) Drug Candidate for Treatment of Infections caused by Staphylococcus Aureus
Feb 11, 2020 11:14 JST

Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces further positive data from its current investigational new drug (IND)-enabling studies for ALS-4
More info..

Aptorum Group Announces Significant Progress of Repurposed Drug Candidate, SACT-1 for Neuroblastoma Targeting IND Submission in H2 2020
Feb 10, 2020 22:58 JST

Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces positive data and development in relation to its repurposed drug candidate, SACT-1, for the treatment of neuroblastoma
More info..

Aptorum Group has initiated IND-Enabling Studies for its ALS-4 Small Molecule Candidate for the Treatment of Infections Caused by Staphylococcus Aureus including MRSA
Sep 10, 2019 13:01 JST

Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces that it has initiated investigational new drug (IND)-enabling studies for ALS-4
More info..

Aptorum Group Announces the Development of Microbiome Drug Candidate Targeting Obesity and Repurposed Drug Candidates Targeting Neuroblastoma
Sep 10, 2019 12:36 JST

Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces the development of two preclinical drug candidates which target obesity and neuroblastoma, respectively.

More info..

Aptorum Group Limited Announces Pricing of Initial Public Offering Dec 07, 2018 15:59 JST Aptorum Group Limited ("Aptorum", or the "Company"), a Hong Kong based pharmaceutical company currently in the preclinical stage, dedicated to developing and commercializing therapeutic projects and diagnostic technologies to tackle unmet medical needs, today announced that on December 3, 2018 More info..